טוען...
Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial
BACKGROUND: Preoperative capecitabine-based chemoradiotherapy (CRT) is feasible for the treatment of resectable locally advanced rectal cancer (LARC). To try to improve efficacy, we conducted a phase II study in which the epidermal growth factor receptor-targeting monoclonal antibody cetuximab was a...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Versita, Warsaw
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3472951/ https://ncbi.nlm.nih.gov/pubmed/23077464 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/v10019-012-0030-2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|